FDA to Investigate Diabetes Drugs for Possible Pancreatic Risk

The U.S. Food and Drug Administration is investigating new unpublished research by a group of scientists that shows a possible link between a class of diabetes drugs known as incretin mimetics and an increased risk of developing pancreatitis or pre-cancerous cells. According to a statement released by the agency on Thursday, the FDA intends to look at the research and the pancreatic samples used by the scientists in their study in order to “further investigate” the questions raised by the team’s initial findings.